Diagnostic Approach to Diabetes Insipidus

Critical Diagnostic Features

The American College of Physicians suggests that a urine osmolality of 170 mOsm/kg is inappropriately low given a serum osmolality of 300 mOsm/kg, indicating diabetes insipidus 1, 2, 3
The detection of inappropriately diluted urine (urine osmolality <200 mOsm/kg H₂O) combined with high-normal or elevated serum sodium is pathognomonic for diabetes insipidus, as recommended by the European Society of Endocrinology 1, 4, 3

The National Institute of Diabetes and Digestive and Kidney Diseases recommends plasma copeptin measurement, with baseline plasma copeptin levels above 21.4 pmol/L being diagnostic for nephrogenic DI in adults 1, 2
The American Heart Association suggests that a desmopressin (DDAVP) trial can confirm central DI, while lack of response indicates nephrogenic DI 2
Genetic testing is recommended if nephrogenic DI is suspected, particularly testing AVPR2 and AQP2 genes, as advised by the Endocrine Society 1, 4, 3

Primary polydipsia would show response to water deprivation with urine concentration, and typically presents with lower serum sodium and osmolality due to excessive water intake, according to the National Academy of Clinical Biochemistry 2
The high-normal serum osmolality (300 mOsm/kg) argues against primary polydipsia, as stated by the American Association for Clinical Chemistry 1, 2

The European Society of Endocrinology recommends that prior to initiating any treatment, serum sodium must be confirmed as normal, and the specific type of DI must be established 3
For central DI, desmopressin is the treatment of choice, while for nephrogenic DI, thiazide diuretics combined with dietary salt restriction and potentially prostaglandin synthesis inhibitors are recommended, as suggested by the American College of Physicians 5, 3

The American College of Radiology recommends that if central DI is confirmed, MRI of the sella with and without contrast using high-resolution pituitary protocols is mandatory to evaluate for hypothalamic-pituitary pathology including tumors, infiltrative processes, or structural abnormalities 6, 7

The Endocrine Society suggests that diabetes insipidus at presentation with a sellar/suprasellar mass strongly suggests craniopharyngioma, histiocytosis, or germ-cell tumor rather than pituitary adenoma, and DI is the most common presenting endocrine disorder in Erdheim-Chester disease (50-70% of cases) and often precedes diagnosis 8

The American College of Physicians recommends that before initiating any treatment for diabetes insipidus, serum sodium should be confirmed as normal, and the specific type of DI (central vs. nephrogenic) should be established 8
The European Society of Endocrinology suggests that desmopressin is the treatment of choice for confirmed central DI, with a starting dose of 2-4 mcg daily as one or two divided doses by subcutaneous or IV injection, and fluid restriction should be initiated during treatment to prevent hyponatremia 8

In patients with suspected diabetes insipidus, the presence of a sellar/suprasellar mass at presentation strongly suggests craniopharyngioma, histiocytosis, or germ-cell tumor rather than pituitary adenoma 9

If central DI is confirmed, MRI of the sella with high-resolution pituitary protocols is mandatory to evaluate for hypothalamic-pituitary tumors, infiltrative processes, and structural abnormalities, with a critical finding being the absence of the posterior pituitary "bright spot" on T1-weighted images 9

Hypokalemia, as seen in patients with diabetes insipidus, requires correction and may suggest underlying aldosteronoma or other endocrinopathy, or be related to polyuria-induced losses 10